“It has been a great experience working with you. The service and guidance you provided are worth every penny. I cannot thank you enough for your help.”

General Field: Pharmaceutical Sciences

Position at the Time of Case Filing: Manager of Product Development

Country of Origin: India

State of Residence at the Time of Filing: Pennsylvania

Approval Notice Date: April 16^th, 2021

Processing Time: 7 days (Premium Processing Requested)

Case Summary:

Holder of a Ph.D. in pharmaceutics and drug delivery, a manager of product development hired our law firm to file an EB-1A (Alien of Extraordinary Ability) petition representing his case. Before agreeing to countersign the retainer agreement, a thorough evaluation of his credentials was required to ensure the possibility of his EB-1A approval. We assessed his documents and established that he does possess an extraordinary ability to continue his research here in the United States. We validated it by elaborating on his qualification, current position, and research background with unique and expansive expertise to contribute significantly to the field of pharmaceutical sciences.

To reinforce our client’s EB-1A case, we detailed his intended research on new drug product development with a portfolio covering a range of therapeutic treatment areas. After a heedful review, we learned that his drug product and process development research is of the utmost importance due to their direct applicability in global efforts to address drug development and disease treatment, extending the fair expectation that he must stay to do so within the United States.

Additionally, we noted the 9 peer-reviewed scientific articles and 4 book chapters he published in international journals, which altogether amassed 308 citations. His findings have influenced many leading researchers in 7 countries, thereby demonstrating that his writings are eminent and widely relied upon in the field. Not only his citations and publications record led his current and future research in the field but the importance of his discoveries is also confirmed by the funding it has received from the National Institutes of Health (NIH), through two separate grants. This funding supports projects that promote the NIH in achieving its national healthcare goals and improving the quality of life in the U.S. Considering the inherent value of his drug delivery, drug product, and process development research, in succession with the government funding of his research, and the high esteem the scientific community holds for his work, it is clear that our client is one of the foremost scientists working in the pharmaceutical sciences field today.

Further, we highlighted that he has conducted 40 reviews for extraordinary and elite journals with very stiff publishing guidelines that enlist the services of only the most accomplished researchers. These statements certainly confirm his excellent work as a peer reviewer and are further evidence of his distinguished status.

Moreover, we incorporated 4 letters of recommendation gathered from fellow renowned experts in the field, confirming how our client’s work is fundamental for improving the therapeutic effect of drugs and public health and fighting illness in the United States. Two of them stated the following:

“Based on all of the above evidence, I hope it is clear that [client’s] expertise and accomplishments have firmly positioned him as one of the leading researchers in the pharmaceutical sciences community. Considering the novelty of his work and its important implications for real-world application, he has much to offer the United States.”

“[Client’s] work is crucial for the field for a multitude of reasons… The high costs, low success rate nature of drug discovery have positioned prodrug approaches such as his critical and cost-effective method for improving the absorption of protease inhibitor drugs, therefore is vital to domestic public health and economy.”

We are pleased that we were able to help our client in securing his EB1A petition approval within 7 days without any further request for evidence. A special thanks to Premium Processing service, a paid option offered by the USCIS, allowing petitioners to enjoy accelerated adjudication. We thank our client for choosing North America Immigration Law Group for representing his EB-1A application and for allowing us to be a part of his success story.